CN105503894A - 1-氧代/酰化-14-酰化的冬凌草甲素衍生物、及其制备方法和应用 - Google Patents

1-氧代/酰化-14-酰化的冬凌草甲素衍生物、及其制备方法和应用 Download PDF

Info

Publication number
CN105503894A
CN105503894A CN201510996590.2A CN201510996590A CN105503894A CN 105503894 A CN105503894 A CN 105503894A CN 201510996590 A CN201510996590 A CN 201510996590A CN 105503894 A CN105503894 A CN 105503894A
Authority
CN
China
Prior art keywords
acylated
oxo
oridonin
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510996590.2A
Other languages
English (en)
Chinese (zh)
Inventor
徐荣臻
荣风光
谢福文
赖洪喜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bunsen Pharmaceutical (shanghai) Co Ltd
Original Assignee
Hangzhou Bensheng Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Bensheng Pharmaceutical Co Ltd filed Critical Hangzhou Bensheng Pharmaceutical Co Ltd
Priority to CN201510996590.2A priority Critical patent/CN105503894A/zh
Publication of CN105503894A publication Critical patent/CN105503894A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201510996590.2A 2012-01-21 2013-01-21 1-氧代/酰化-14-酰化的冬凌草甲素衍生物、及其制备方法和应用 Pending CN105503894A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510996590.2A CN105503894A (zh) 2012-01-21 2013-01-21 1-氧代/酰化-14-酰化的冬凌草甲素衍生物、及其制备方法和应用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2012/000124 2012-01-21
CNPCT/CN2012/000124 2012-01-21
CN201510996590.2A CN105503894A (zh) 2012-01-21 2013-01-21 1-氧代/酰化-14-酰化的冬凌草甲素衍生物、及其制备方法和应用
CN201380004934.6A CN104039796B (zh) 2012-01-21 2013-01-21 1-氧代/酰化-14-酰化的冬凌草甲素衍生物、及其制备方法和应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380004934.6A Division CN104039796B (zh) 2012-01-21 2013-01-21 1-氧代/酰化-14-酰化的冬凌草甲素衍生物、及其制备方法和应用

Publications (1)

Publication Number Publication Date
CN105503894A true CN105503894A (zh) 2016-04-20

Family

ID=48798683

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201510996590.2A Pending CN105503894A (zh) 2012-01-21 2013-01-21 1-氧代/酰化-14-酰化的冬凌草甲素衍生物、及其制备方法和应用
CN201380004934.6A Expired - Fee Related CN104039796B (zh) 2012-01-21 2013-01-21 1-氧代/酰化-14-酰化的冬凌草甲素衍生物、及其制备方法和应用
CN201510995686.7A Expired - Fee Related CN105418627B (zh) 2012-01-21 2013-01-21 1‑氧代/酰化‑14‑酰化的冬凌草甲素衍生物、及其制备方法和应用
CN201510997476.1A Expired - Fee Related CN105601622B (zh) 2012-01-21 2013-01-21 1-氧代/酰化-14-酰化的冬凌草甲素衍生物、及其制备方法和应用

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201380004934.6A Expired - Fee Related CN104039796B (zh) 2012-01-21 2013-01-21 1-氧代/酰化-14-酰化的冬凌草甲素衍生物、及其制备方法和应用
CN201510995686.7A Expired - Fee Related CN105418627B (zh) 2012-01-21 2013-01-21 1‑氧代/酰化‑14‑酰化的冬凌草甲素衍生物、及其制备方法和应用
CN201510997476.1A Expired - Fee Related CN105601622B (zh) 2012-01-21 2013-01-21 1-氧代/酰化-14-酰化的冬凌草甲素衍生物、及其制备方法和应用

Country Status (6)

Country Link
US (1) US9902736B2 (enExample)
EP (1) EP2805955B1 (enExample)
JP (1) JP6286365B2 (enExample)
CN (4) CN105503894A (enExample)
DK (1) DK2805955T3 (enExample)
WO (1) WO2013107429A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106866695A (zh) * 2017-02-22 2017-06-20 石家庄学院 冬凌草甲素衍生物及其制备和应用
CN106883267A (zh) * 2017-02-22 2017-06-23 石家庄学院 Vbe冬凌草甲素衍生物及其制备和应用
CN108017600A (zh) * 2016-10-31 2018-05-11 南开大学 六种来源于荔枝草的萜类化合物及其制备方法和用途
WO2021237609A1 (en) * 2020-05-28 2021-12-02 Tsinghua University Novel use of oridonin or oridonin derivative
CN114874172A (zh) * 2022-06-29 2022-08-09 南充市中心医院 一种冬凌草甲素衍生物及其制备方法和医用用途
CN117466906A (zh) * 2023-09-19 2024-01-30 中国人民解放军海军军医大学 冬凌草甲素衍生物及其制备方法和药物组合物与应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103467474B (zh) * 2013-09-17 2016-06-01 中国药科大学 1,6,7,14-位取代的冬凌草甲素衍生物、制备方法及用途
CN104003998B (zh) * 2014-05-12 2017-01-11 中国药科大学 冬凌草甲素14-o-取代氮芥衍生物、制备方法及用途
CN105131009A (zh) * 2014-05-30 2015-12-09 江苏恒瑞医药股份有限公司 L-丙氨酸-(14-冬凌草甲素)酯三氟乙酸盐的i型结晶及制备方法
CN105985352B (zh) * 2015-02-04 2018-05-15 中国药科大学 冬凌草甲素荧光探针、制备及其在靶细胞定位中的用途
CN105968072A (zh) * 2016-05-18 2016-09-28 沈阳药科大学 毛栲利素衍生物的制备方法及其抗菌活性的新用途
CN106749305B (zh) * 2016-11-16 2019-02-22 中国药科大学 A-环改造的冬凌草甲素衍生物、其制备方法及用途
CN108299458B (zh) * 2017-12-28 2020-10-02 青岛海洋生物医药研究院股份有限公司 冬凌草甲素衍生物及其制备方法和应用
CN113698415A (zh) * 2020-05-22 2021-11-26 中国药科大学 一种新型的冬凌草甲素类似物及衍生物、其制备方法及医药用途
CN112979672B (zh) * 2021-03-05 2022-03-11 郑州大学 11,20-二羰基冬凌草甲素14-o酯化系列衍生物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101139350B (zh) * 2007-10-15 2010-06-02 中国药科大学 冬凌草甲素类衍生物、其制备方法及用途
CN102295649A (zh) * 2011-08-31 2011-12-28 中国药科大学 具有抗肿瘤活性的冬凌草甲素及6，7-开环冬凌草甲素含氟衍生物、制备方法及用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101723951A (zh) 2008-10-24 2010-06-09 山东靶点药物研究有限公司 冬凌草甲素衍生物及其制备方法
FR2944435B1 (fr) * 2009-04-17 2011-05-27 Sederma Sa Composition cosmetique comprenant de l'oridonine
CN102002051B (zh) 2010-10-18 2013-06-19 中国药科大学 具有抗肿瘤活性的ent-6,7-开环贝壳杉烯型冬凌草甲素衍生物、其制备方法及用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101139350B (zh) * 2007-10-15 2010-06-02 中国药科大学 冬凌草甲素类衍生物、其制备方法及用途
CN102295649A (zh) * 2011-08-31 2011-12-28 中国药科大学 具有抗肿瘤活性的冬凌草甲素及6，7-开环冬凌草甲素含氟衍生物、制备方法及用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
伍旭等: "冬凌草甲素衍生物的制备和评价", 《中草药》 *
徐星星，等: "冬凌草甲素衍生物的合成及其抗t( 8; 21)白血病活性研究", 《中国药物化学杂志》 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108017600A (zh) * 2016-10-31 2018-05-11 南开大学 六种来源于荔枝草的萜类化合物及其制备方法和用途
CN108017600B (zh) * 2016-10-31 2021-10-01 南开大学 六种来源于荔枝草的萜类化合物及其制备方法和用途
CN106866695A (zh) * 2017-02-22 2017-06-20 石家庄学院 冬凌草甲素衍生物及其制备和应用
CN106883267A (zh) * 2017-02-22 2017-06-23 石家庄学院 Vbe冬凌草甲素衍生物及其制备和应用
CN106866695B (zh) * 2017-02-22 2018-12-21 石家庄学院 冬凌草甲素衍生物及其制备和应用
WO2021237609A1 (en) * 2020-05-28 2021-12-02 Tsinghua University Novel use of oridonin or oridonin derivative
CN114874172A (zh) * 2022-06-29 2022-08-09 南充市中心医院 一种冬凌草甲素衍生物及其制备方法和医用用途
CN114874172B (zh) * 2022-06-29 2023-09-05 庞磊 一种冬凌草甲素衍生物及其制备方法和医用用途
CN117466906A (zh) * 2023-09-19 2024-01-30 中国人民解放军海军军医大学 冬凌草甲素衍生物及其制备方法和药物组合物与应用

Also Published As

Publication number Publication date
US9902736B2 (en) 2018-02-27
CN104039796A (zh) 2014-09-10
EP2805955B1 (en) 2018-10-31
JP6286365B2 (ja) 2018-02-28
DK2805955T3 (en) 2019-02-18
CN105601622A (zh) 2016-05-25
JP2015504076A (ja) 2015-02-05
CN105601622B (zh) 2019-03-05
EP2805955A4 (en) 2015-06-10
EP2805955A1 (en) 2014-11-26
CN105418627A (zh) 2016-03-23
US20140364490A1 (en) 2014-12-11
CN105418627B (zh) 2018-02-23
CN104039796B (zh) 2016-10-19
WO2013107429A1 (zh) 2013-07-25

Similar Documents

Publication Publication Date Title
CN105418627B (zh) 1‑氧代/酰化‑14‑酰化的冬凌草甲素衍生物、及其制备方法和应用
CN103946231B (zh) 齐墩果酸酰胺化衍生物、及其制备方法和应用
CN105037380B (zh) 吲哚类鬼臼毒素衍生物、其制备方法、药物组合物及应用
JP6298768B2 (ja) ７−置換ハンファンギチンｂ誘導体、その調製方法及び使用
JP6149043B2 (ja) ２−アミノ化メチレン又は２−エステル化メチレンタンシノン誘導体、並びにその調製方法及び使用
CN110964078A (zh) 具有抗肺癌作用的常春藤皂苷元类化合物h-x及其制备方法和应用
JP2015523349A (ja) ポリフィリンｉのアシル化誘導体、その調製方法及び使用
CN103373986B (zh) 克里唑替尼前药及其制备方法与用途
JP6068472B2 (ja) アミノ化ホモハリントニン誘導体、その調製方法及び使用
JP6059734B2 (ja) ２−アルキル−又は２−アリール−置換タンシノン誘導体、その調製方法及び適用
CN104039794B (zh) 7‑位取代的汉防己乙素衍生物、及其制备方法和应用
CN104334571B (zh) 重楼皂苷i的酰化衍生物、及其制备方法和应用
CN103958490B (zh) 2-位烷基或芳香基取代的丹参酮衍生物、及其制备方法和应用
CN103635476B (zh) 高三尖杉酯碱的酰化衍生物、及其制备方法和应用
JP5993455B2 (ja) ホモハリントニンアシル化誘導体、その調製方法及び使用
CN102712655B (zh) 小檗胺的二酰亚胺化衍生物、其制备方法和应用
CN117567457A (zh) 噻唑酮亚砜和砜类化合物及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20180510

Address after: Room 102, No. 131, Kai Qing Road, Pudong New Area, Shanghai

Applicant after: Bunsen Pharmaceutical (Shanghai) Co., Ltd.

Address before: 310051 4 4, 6 Jiangling Road, Binjiang District, Hangzhou, Zhejiang.

Applicant before: Hangzhou Bensheng Pharmaceutical Co., Ltd.

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20160420

RJ01 Rejection of invention patent application after publication